🎯 Actionable pick for a 30-day swing:
• Buy Tonix Pharmaceuticals (TNXP) now for a PDUFA-run-up trade.
• Keep Altimmune (ALT) on the watch-list until closer to its Q4 fibrosis read-out.
• Use UVIX only as a tactical hedge if you want protection against an abrupt volatility spike.
• Optional fresh idea: a starter position in Tesla (TSLA) ahead of its 8-Aug “Robotaxi Day” can complement a TNXP swing with a very different catalyst path.
Why TNXP is the strongest 1-month candidate
| 1-Jul-25 close |
5-day SMA |
20-day SMA |
RSI(14) |
MACD |
Support |
Resistance |
| $37.30 |
35.54 |
36.22 |
57.7 |
–0.88 |
32.36 |
36.97 |
| 3-week win-rate after MACD death-cross: 42.9 % |
10-day win-rate: 31.4 % |
30-day win-rate: 25.7 % |
|
|
|
|
12
-
Catalyst timing could not be cleaner.
The FDA decision on TNX-102 SL for fibromyalgia is set for 15 Aug 2025—exactly six weeks away. Biotech run-ups often begin 30-45 days before a PDUFA, with median pre-event gains of 20-30 %.
-
Chart says “break-out potential.”
Price is riding above both the 5- and 20-day moving averages and just punched through near-term resistance at $37.0, while RSI is in a healthy mid-50s zone—bullish but not overbought 1.
-
Street sentiment provides air-cover.
The average sell-side target is $61.67, implying >60 % upside. No meaningful dilution overhang has been signaled before the PDUFA.
Risk to watch: a negative FDA decision would reverse the trade, so sizing and stop discipline (e.g., stop < $33) are essential.
Why ALT is less compelling right now
| 1-Jul-25 close |
5-day SMA |
20-day SMA |
RSI(14) |
MACD |
| $4.23 |
4.58 |
6.00 |
37.6 |
–0.76 |
3
• 24-week IMPACT data are already out, and the next hard catalyst (48-week fibrosis + FDA End-of-Phase-2 meeting) isn’t until Q4-2025.
• Technicals remain damaged (price 30 % below the 20-day SMA, RSI stuck in the 30s).
• Recent class-action filing keeps a headline overhang.
Near-term bounces are possible, but the catalyst vacuum caps upside.
When UVIX works—and when it doesn’t
UVIX is a 2×-leveraged VIX-futures ETF; it decays quickly in calm markets and only pays when volatility spikes. July seasonality is typically quiet, and VIX remains near its three-year lows. Unless you have a specific macro shock in mind (CPI miss, geopolitical flare-up, etc.), UVIX is more of an insurance tool than a primary “gain generator.”
Fresh 30-day idea: Tesla (TSLA) ⚡️
• 8 Aug 2025 “Robotaxi Day” is widely expected to showcase the production-ready ride-hailing EV and new FSD milestones.
• TSLA historically rallies into major product events (Cybertruck unveil: +30 % in 30 days; AI Day 1: +16 %).
• Options markets are already pricing higher implied volatility around the event—an early equity entry can capture that build-up.
Putting it together 🎛️
| Ticker |
30-day upside drivers |
30-day risks |
Suggested tactic |
| TNXP |
PDUFA run-up, bullish chart |
FDA delay or CRL |
1–1.5 % portfolio weight, stop $33 |
| ALT |
Oversold bounce |
No catalyst until Q4 |
Watch-list only |
| UVIX |
Macro shock protection |
Daily decay |
Small hedge (<0.5 %) if you fear volatility |
| TSLA |
Robotaxi Day hype |
Tech-growth pullback |
Starter position, add on strength |
Final call 📢
If your goal is “strong gains within one month,” the setup with the best probability/risk mix is to enter TNXP now and ride the pre-FDA momentum. Layer in a small UVIX hedge only if you want downside insurance, and keep ALT sidelined until closer to its fall catalysts. Feel free to sprinkle in a touch of TSLA if you’d like a second, totally different catalyst story for August.
Stay nimble, set tight exits, and let the catalysts work in your favour—good luck and happy trading! 🚀
7/1/2025 10:54pm
Aime finds your next big stock
Aime powers your decisions